Highlights on endothelins: A review

Pharmacological Research

Volumn 36, Issue 5, 1997, Pages 339-351

  Mateo, Ana Ortega ^a   De Artiñano, Amaya Aleixandre ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Endothelins; Endothelium; Vascular smooth muscle

Indexed keywords

AMINO ACID; CALCIUM ION; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN C RECEPTOR; ENDOTHELIN CONVERTING ENZYME; NITRIC OXIDE; PEPTIDE; PROSTACYCLIN; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; AMINO ACID SEQUENCE; BASOLATERAL MEMBRANE; CALCIUM CELL LEVEL; ENDOTHELIUM CELL; HEART FAILURE; HYPERTENSION; PRECURSOR; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAYNAUD PHENOMENON; RECEPTOR BINDING; REVIEW; SUBARACHNOID HEMORRHAGE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASOSPASM;

EID: 0031278932     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1997.0246     Document Type: Review

References (135)

1. 1. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-5.
2. 2. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
3. 3. Furchgott RF. Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activatable inhibitory factor from retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In: Vanhoutte PM. ed. Vasodilatation: Vascular Smooth Muscle, Peptides, Autonomic Nerves and Endothelium. New York: Raven Press, 1988; pp. 401-14.
4. 4. Ignarro LJ, Byrns RE, Wood KS. Biochemical and pharmacological properties of endothelium-derived relaxing factor and its similarity to nitric oxide radical. In: Vanhoutte PM. ed. Vasodilatation: Vascular Smooth Muscle, Peptides, Autonomic Nerves and Endothelium. New York: Raven Press, 1988; pp. 427-36.
5. 5. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
6. 6. De Mey JG, Vanhoutte PM. Role of the intima in cholinergic and purinergic relaxation of isolated canine femoral arteries. J Physiol 1981; 316: 347-55.
7. 7. De Mey JG, Vanhoutte PM. Heterogeneous behavior of the canine arterial and venous wall: importance of the endothelium. Circulation Res 1982; 51: 439-47.
8. 8. De Mey JG, Vanhoutte PM. Anoxia and endothelium dependent reactivity of the canine femoral artery. J Physiol 1983; 335: 65-74.
9. 9. Gillespie MN, Owasoyo JO, McMurtry IF, O'Brien RF. Sustained coronary vasoconstriction provoked by a peptidergic substance released from endothelial cells in culture. J Pharmacol Exp Ther 1985; 236: 339-43.
10. 10. Hickey KA, Rubanyi G, Paul RJ, Highsmith RF. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985; 248: C550-6.
11. 11. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazake Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-15.
12. 12. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T. Goto K, Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86: 2863-7.
13. 13. Sakurai T, Yanagisawa M, Inoue A, Ryan US, Kimura S, Mitsui I, Goto K, Masaki T. cDNA cloning, sequence analysis and tissue distribution of rat preproendothelin-1 mRNA. Biochem Biophys Res Commun 1991; 175: 44-7.
14. 14. Bloch KD, Eddy RL, Shows TB, Quertermous T. cDNA cloning and chromosomal assignment of the gene encoding endothelin-3. J Biol Chem 1989; 264: 18156-61.
15. 15. Ohkubo S, Ogi K, Hosoya M, Matsumoto H, Suzuki N, Kimura C, Ondo H, Fujino M. Specific expression of human endothelin-2 (ET-2) gene in a renal adenocarcinoma cell line. FEBS Lett 1990; 274: 136-40.
16. 16. Shiba R, Sakurai T, Yamada G, Morimoto H, Saito A, Masaki T, Goto K. Cloning and expression of rat preproendothelin-3 cDNA. Biochem Biophys Res Commun 1992; 588-94.
17. 17. Ambar I, Kloog Y, Schvartz I, Haxum E, Sokolovsky M. Competitive interaction between endothelin and sarafotoxin: binding and phosphoinositides hydrolysis in rat atria and brain. Biochem Biophys Res Commun 1989; 158: 195-201.
18. 18. Robin C. Endothelin receptor ligands. Res Biochem Int 1995; 2: 1-6.
19. 19. Kimura S, Kasuya Y, Sawamura T, Shinmi O, Sugita Y, Yanawisawa M, Goto K, Masaki T. Structure-activity relationship of endothelin: importance of the terminal moiety. Biochem Byophis Res Commun 1988; 156: 1182-6.
20. 20. Nakajima K, Kubo S, Kumagaye SI, Nishio H, Tsunemi N, Inui T, Kuroda H, Chino N, Watanave TX, Kimura T, Sakakibara S. Structure-activity relationship of endothelin: importance of charged groups. Biochem Biophys Res Commun 1989; 163: 424-9.
21. 21. Emori T, Hirata Y, Ohta K, Kanno K, Eguchi S, Imai T, Schichiri M, Marumo F. Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension 1991; 18: 165-70.
22. 22. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990; 85: 587-90.
23. 23. Warner TD, Schmidt HHHW, Murad F. Interactions of endothelins and EDRF in bovine native endothelial cells: selective effects of endothelin-3. Am J Physiol 1992; 262: H1600-5.
24. 2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 1994; 269: 11938-44.
25. 25. Kohno M, Horio T, Yokokawa K, Kurihara N, Takeda T. C-type natriuretic peptide inhibits thrombin-and angiotensin II-stimulated endothelin release via cyclic guanosine 3′, 5′-mono-phosphate. Hypertension 1992; 19: 320-5.
26. 26. Kohno M, Yokokawa K, Horio T, Yasunari K, Murakawa K, Takeda T. Atrial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta. Circ Res 1992; 70: 241-7.
27. 27. Emori T, Hirata Y, Imai T, Eguchi S, Kano K. Cellular mechanism of natriuretic peptides induced inhibition of endothelin-1 biosynthesis in rat endothelial cells. Endocrinology 1993; 133: 2474-80.
28. 28. Imai T, Hirata Y, Emori T, Marumo F. Heparin has an inhibitory effect on endothelin-1 synthesis and release by endothelial cells. Hypertension 1993; 21: 353-8.
29. 29. Yokokawa K, Tahara H, Kohno M, Mandal AK, Yanagisawa M, Takeda T. Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells. J Clin Invest 1993; 92: 2080-5.
30. 30. Griffith TM, Edwards DH, Davis RL, Harrison TJ, Evans KT. Endothelium-dependent responses in the peripheral microcirculation. In: Vanhoutte PM. ed. Relaxing and Contracting Factors. Clifton NJ: Human, 1988; pp. 389-416.
31. 31. Miller V, Burnett JC Jr. Modulation of NO and endothelin by chronic increases in blood flow in canine femoral arteries. Am J Physiol 1992; 263: H103-8.
32. 32. Kuchan MJ, Frangos JA. Shear stress regulates endothelin-1 release via protein kinase C and cGMP in cultured endothelial cells. Am J Physiol 1993; 264: H150-6.
33. 33. Ikegawa R, Matsumura Y, Tsukahara Y, Takaoka M, Morimoto S. Phosphoramidon, a metalloprotease inhibitor, supresses the secretion of endothelin-1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme. Biochem Blophys Res Commun 1990; 171: 669-75.
34. 34. Opgenorth TJ, Wu-Wong JR, Shiosaki K. Endothelin-converting enzymes. FASEB J 1992; 6: 2653-9.
35. 35. Xu D, Emoto N, Giaid A, Slaughter C, Kaus S, DeWit D, Yanagisawa M. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994; 78: 473-85.
36. 36. Keller PM, Lee CP, Fenwick AE, Atkinson ST, Elliot JD, DeWolf WE Jr. Endothelin converting enzyme: substrate specificity and inhibition by novel analogs of phosphoramidon. Biochem Biophys Res Commun 1996; 223(2): 372-8.
37. 37. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 1995; 270: 15262-8.
38. 38. Yoshimoto S, Ishizaki Y, Sasaki T, Murota S. Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. Stroke 1991; 22: 378-83.
39. 39. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhausl W, Binder BR. Polar secretion ef endothelin-1 by cultured endothelial cells. J Biol Chem 1992; 267: 16066-8.
40. 40. Warner TD, Battistini B, Doherty AM, Corder R. Endothelin receptor antagonists: actions and rationale for their development. Biochem Pharmacol 1994; 48(4): 625-35.
41. 41. Battistini B, D'Orléans-Juste P, Sirois P. Biology of disease. Endothelins: circulating plasma levels and presence in other biologic fluids. Lab Invest 1993; 68: 600-28.
42. 42. Howard PG, Plumpton C, Davenport AP. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. Hypertension 1992; 10: 1379-86.
43. 125I}endothelin-1 binding data. Life Sci 1992; 51: 1869-76.
44. 44. Hosoda K, Nakao K, Arai H, Suga S, Ogawa Y, Mukoyama M. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 1991; 287: 23-6.
45. 45. Sakamoto A, Yanagisawa M, Sakurai M, Takuwa Y, Masaki T. Cloning and functional expression of human cDNA for the ETB endothelin receptor. Biochem Biophys Res Commun 1991; 178: 656-63.
46. B receptors mediate vascular smooth muscle contraction. Br J Pharmacol 1992; 107: 858-60.
47. B-like receptors. Biochem Biophys Res Commun 1992; 184: 100-06.
48. 48. Warner TD, Allcock GH, Corder R, Vane JR. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol 1993; 110: 777-82.
49. 49. Sudjarwo SA, Hori M, Takai M, Urade Y, Okada T, Karaki H. A novel subtype of endothelin B receptor mediating contraction in swine pulmonary vein. Life Sci 1993; 53: 431-7.
50. 50. Lippton H, Goff J, Hyman A. Effects of endothelin in the systemic and renal vascular beds in vivo. Eur J Pharmacol 1988; 155: 197-9.
51. 51. Wright CE, Fozard JR. Regional vasodilatation is a prominent feature of the haemodynamic response to endothelin in anesthetized spontaneously hypertensive rats. Eur J Pharmacol 1988; 155: 201-3.
52. 52. Winquist RJ, Bunting PB, Garsky VM, Lumma PK, Schofield TL. Prominent depressor response to endothelin in spontaneously hypertensive rats. Eur J Pharmacol 1989; 163: 199-203.
53. 53. Miyauchi T, Ishikawa T, Tomobe Y, Yanagisawa M, Kimura S, Sugishita Y, Ito I, Goto K, Masaki T. Characteristics of presser response to endothelin in spontaneously hypertensive and Wistar-Kyoto rats. Hypertension 1989; 14: 427-34.
54. 54. McMurdo L, Corder R, Thiemermann C, Vane JR. Incomplete inhibition of the presser effects of endothelin-1 and related peptides in the anaesthetized rat with BQ-123 provides evidence for more than one vasoconstrictor receptor. Br J Pharmacol 1993; 108: 557-61.
55. 55. Warner TD, Mitchell JA, DeNucci G, Vane JR. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol 1989; 13(Suppl. 5): 85-8.
56. 56. Filep JG, Földes-Filep E, Rousseau A, Sirois P, Fournier A. Vascular responses to endothelin-1 following inhibition of nitric oxide synthesis in conscious rat. Br J Pharmacol 1993; 110: 1213-21.
57. 57. Masaki T. Possible role of endothelin in endothelial regulation of vascular tone. Annu Rev Pharmacol Toxicol 1995; 35: 235-55.
58. 58. Mehta JL, Lawson DL, Yang BC, Mehta P, Nichols WW. Modulation of vascular tone by endothelin-1: role of preload, endothelial integrity and concentration of endothelin-1. Br J Pharmacol 1992: 127-32.
59. 59. Inagami T, Naruse M, Hoover R. Endothelium as an endocrine organ. Annu Rev Physiol 1995; 57: 171-89.
60. 60. Kimura S, Kasuya Y, Sawamura T, Shinmi O, Sugita Y, Yanagisawa M, Goto K, Masaki T. Conversion of big endothelin-1 to 21 residue endothelin-1 is essential for expression of full vasoconstrictor activity: structure activity relationships of big endothelin-1. J Cardiovasc Pharmacol 1989; 13(Suppl. 5): S5-S7.
61. 61. Fukuroda T, Noguchi K, Tsuchida S, Nishikibe M, Ikemoto F, Okada K, Yana M. Inhibition of biological actions of big endothelin 1 by phosphoramidon. Biochem Biophys Res Commun 1990; 172: 390-5.
62. 62. McMahon EG, Palomo MA, Moore WM, McDonald JF, Stern MK. Phosphoramidon blocks the presser activity of porcine big endothelin-1 (1-39) in vivo and conversion of big endothelin-1 (1-39) to endothelin-1 (1-21) in vitro. Proc Natl Acad Sci USA 1991; 88: 703-7.
63. 63. Hirata Y, Yoshimi H, Takata S, Watanabe TX, Kumagai S, Nakajima K, Sakakibara S. Cellular mechanism of action by a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. Biochem Biophys Res Commun 1988; 154: 868-75.
64. 64. Van Renterghem C, Vigne P, Barhanin J, Schmid-Alliana A, Frelin C, Lazdunski M. Molecular mechanism of action of the vasoconstrictor peptide endothelin. Biochem Biophys Res Commun 1988; 157: 977-85.
65. 3/diacylglycerol (DG) second messenger generation in endothelin-stimulated A-10 vascular smooth muscle cells. FASEB J 1989; 3: A719.
66. 66. Highsmith R, Pang DC, Rapoport RM. Endothelial cell-derived vasoconstrictors: mechanisms of action in vascular smooth muscle. J Cardiovasc Pharmacol 1989; 13(Suppl. 5): S36-44.
67. 67. Marsden PA, Danthuluri NR, Brenner BN, Ballermann BJ, Brock TA. Endothelin action on vascular smooth muscle involves inositol triphosphate and calcium mobilization. Biochem Biophys Res Commun 1989; 158: 86-93.
68. 68. Highsmith RF, Schmidt DJ, Pang DC, Stauderman KA, Rapoport RM. Mechanisms of action of endothelial cell-derived constricting factors. In: Rubanyi GM, Vanhoutte PM. eds. Endothelium Derived Contracting Factors. Basel: Karger, 1990; pp. 50-9.
69. 69. Pang DC, Johns A, Patterson K, Botelho LHP, Rubanyi GM. Cellular mechanisms of action of endothelin in isolated canine coronary arteries. In: Rubanyi GM, Vanhoutte PM. eds. Endothelium Derived Contracting Factors. Basel: Karger, 1990; pp. 66-72.
70. 70. Liu CY, Sturek M. Attenuation of endothelin-1-induced calcium response by tyrosine kinase inhibitors in vascular smooth muscle cells. Am J Physiol 1996; 270: C1825-33.
71. 71. Golfman LS, Hata T, Beamish RE, Dhalla NS. Role of endothelin in heart function in health and disease. Can J Cardiol 1993; 9: 635-53.
72. 72. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989; 78: 225-8.
73. 73. Bobik A, Grooms A, Millar JA, Mitchel A, Grinpukel S. Growth factor activity of endothelin on vascular smooth muscle. Am J Physiol 1990; 258: C408-15.
74. + exchange, c-fos expression, and mitogenesis in rat mesangial cells. J Clin Invest 1989; 83: 708-12.
75. 75. Takimoto M, Inui T, Okada T, Urade Y. Contraction of smooth muscle by activation of endothelin receptors on autonomic neurons. FEBS Lett 1993; 324: 277-82.
76. C receptor) from Xenopus laevis dermal melanophores. J Biol Chem 1993; 268: 19126-33.
77. 77. Schiffrin EL. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension 1995; 25: 1135-43.
78. 78. Nishimura M, Takahashi H, Matsusawa M. Chronic intracerebroventricular infusions of endothelin elevate arterial pressure in rats. J Hypertens 1991; 9: 71-6.
79. 79. Wong-Dusting HK, La M, Rand MJ. Mechanism of the effects of endothelin on responses to noradrenaline and sympathetic nerve stimulation. Clin Exp Pharmacol Physiol 1990; 17: 269-73.
80. 80. Rakugi H, Tabuchi Y, Nakamura M. Endothelin activates the vascular renin-angiotensin system in rat mesenteric arteries. Biochem Int 1990; 21: 867-72.
81. 81. Coza EN, Gómez-Sanchez CE, Foecking MF. Endothelin binding to cultured calf adrenal glomerulosa cells and stimulation of aldosterone secretion. J Clin Invest 1989; 84: 1032-5.
82. 82. Boarder MR, Marriott DB. Characterisation of endothelin-1 stimulation of catecholamine release from adrenal chromaffin cells. J Cardiovasc Pharmacol 1989; 13: S223-4.
83. 83. Ishikawa T, Yanagisawa M, Kimura S. Positive inotropic actions of novel vasoconstrictor peptide on guinea pig atria. Am J Physiol 1988; 255: H970-3.
84. 84. McClellan G, Weisberg A, Winegrad S. Effect of endothelin-1 on actomyosin ATPase activity. Implications for the efficiency of contraction. Circ Res 1996; 78(6): 1044-50.
85. 85. Rabelink TJ, Kaassjager KAH, Boer P. Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int 1994; 46: 376-8.
86. 86. Larivière R, Day R, Schiffrin EL. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1993; 21: 916-20.
87. 87. Day R, Larivière R, Schiffrin EL. In situ hybridization shows increased endothelin-1 mRNA levels in endothelial cells of blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Am J Hypertens 1995; 8: 294-300.
88. 88. Schiffrin EL, Larivière R, Li J-S, Sventek P, Touyz RM. Deoxycorticosterone acetate plus salt induce overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneusly hypertensive rats. Hypertension 1995; 25: 769-73.
89. 89. Sventek P, Li J-S, Grove K, Deschepper CF, Schiffrin EL. Vascular structure and expression of endothelin-1 gene in L-NAME-treated spontaneusly hypertensive rats. Hypertension 1996; 27: 49-55.
90. 90. Larivière R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneusly hypertensive rats. Hypertension 1993; 21: 294-300.
91. 91. Larivière R, Sventek P, Thibault G, Schiffrin EL. Expression of endothelin-1 gene in blood vessels of adult spontaneusly hypertensive rats. Life Sci 1995; 56: 1889-96.
92. 92. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, Oda H, Kuwaki T, Cao W, Kamada N, Hishage K, Ouchi Y, Azuma S, Toyada Y, Ishikawa T, Kumada M, Yazaki Y. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994; 368: 703-10.
93. 93. Schiffrin EL, Deng LY, Sventek P, Day R. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens 1997; 15: 57-63.
94. 94. Granger JP. Endothelin, the kidney, and hypertension. J Physiol Biochem 1997; 53(1): 37.
95. 95. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of endothelin 1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-9.
96. 96. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin 1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114: 464-9.
97. 97. Taylor RN, Varma M, Teng NN, Roberts JM. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab 1990; 71: 1675-7.
98. 98. Clark BA, Halvorson L, Sachs B, Epstein FH. Plasma endothelin levels in preeclampsia: elevation and correlation with uric acid levels and renal impairment. Am J Obstet Gynecol 1992; 166: 962-8.
99. 99. Hasegawa K, Fujiwara H, Doyama K, Inada T, Ohtani S, Fujiwara T, Hosoda K, Nakao K, Sasayama S. Endothelin-1-selective receptor in the arterial intima of patients with hypertension. Hypertension 1994; 23: 288-93.
100. 100. Miyauchi T, Yanagisawa M, Tomizawa T. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet 1989; 2: 53-4.
101. 101. Omland T, Lie RT, Aakvaag A. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-9.
102. 102. Zeither AM, Goebel H, Schachlinger V. Tissue endothelin-1 inmunoreactivity in the active coronary atherosclerotic plaque. Circulation 1995; 91: 1081-8.
103. 103. Grover GJ, Sleph PG, Fox M. Role of endothelin-1 and big endothelin-1 in modulating coronary artery vascular tone, contractile function and severity of ischaemia in rat hearts. J Pharmacol Exp Ther 1992; 263: 1074-82.
104. 104. Grover GJ, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in canine model of coronary occlusion and reperfusion. Cardiovasc Res 1993; 27: 1613-8.
105. 105. Kon V, Suguira M, Inagami T. Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 1990; 37: 1487-91.
106. 106. Kaddoura S, Curzen NP, Evans TW, Firth J, Poole-Wilson PA. Tissue expression of endothelin-1 mRNA in endotoxaemia. Biochem Biophys Res Commun 1996; 196: 661-5.
107. 107. Oldroy SD, Haylor JL, Morcos SK. Bosentan, an orally active endothelin antagonist: effect on the renal response to contrast media. Radiology 1995; 196: 661-5.
108. 108. Firth JD, Raine AEG, Ratcliffe PJ. Endothelin: an important factor in acute renal failure? Lancet 1988; 2: 1179-82.
109. 109. Shibouta Y, Suzuki N, Shino A. Pathophysiological role of endothelin in acute renal failure. Life Sci 1990; 46: 1611-18.
110. 110. Katoh T, Chang H, Uchida S. Direct effects of endothelin in rat kidney. Am J Physiol 1990; 258: F397-402.
111. 111. Tomita K, Ujiie K, Nakanishi T, Tomita S, Matsuda O. Plasma endothelin levels in patients with acute renal failure. N Engl J Med 1989; 324: 1127.
112. 112. Wilkes BM, Pearl AR, Mento PF, Maiti ME, Macica CM. Glomerular endothelin receptors during initiation and maintenance of ischemic acute renal failure in rats. Am J Physiol 1991; 260: F110-18.
113. 113. Gellai M, Jugus M, Fletcher T, Nambi P, Ohlstein EH, Elliott JD, Brooks DP. Nonpeptide endothelin receptor antagonists V: Prevention and reversal of acute renal failure in the rat by SB 209670. J Pharmacol Exp Ther 1995; 275: 200-6.
114. 114. Yamada K, Yoshida S. Role of endogenous endothelin on renal function in rats. Am J Physiol 1991; 260: F34-8.
115. 115. Alafaci C, Jansen I, Arbad MAR. Enhanced vasoconstrictor effect of endothelin in cerebral arteries from rats with subarachnoid haemorrhage. Acta Physiol Scand 1990; 318: 317-19.
116. 116. Schini VB, Hendrickson H, Heublein DM. Thrombin enhances the release of endothelin from porcine aortic cells. Eur J Pharmacol 1989; 165: 333-4.
117. 117. Mayberg MR, Okada T, Bark DH. The role of haemoglobin in arterial narrowing after subarachnoid haemorrhage. J Neurosurg 1990; 72: 634-40.
118. 118. Masaoka H, Suzuki R, Hirata Y. Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet 1989; 2: 1402.
119. 119. Seiffert V, Löffler BM, Zimmermann M. Endothelin concentrations in patients with aneurysmal subarachnoid haemorrhage. J Neurosurg 1995; 82: 55-62.
120. 120. Suzuki H, Masaoka H, Hirata Y. The role of endothelin-1 in the origin of cerebral vasospasm in patients with aneurysmal subarachnoid haemorrhage. J Neurosurg 1992; 77: 96-100.
121. 121. Clozel M, Breu V, Burri K. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993; 365: 759-61.
122. 122. Fyhrquist F, Saijonmaa O, Metsarinne K. Raised plasma endothelin-1 concentration following cold presser test. Biochem Biophys Res Commun 1990; 169: 217-21.
123. 123. Zamora MR, O'Brien RF, Rutherford RB. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 1990; 336: 1144-7.
124. 124. Urade Y, Fujitani K, Oda T, Watakabe I, Umemura M, Takai M, Okada T, Sakata K, Karaki H. [Cys11-Cys15]-endothelin-1 (11-21), IRL 1038, is an antagonist specific for endothelin B receptors. FEBS Lett 1992; 311: 12.
125. 125. Sakurai T, Goto K. Endothelins: vascular actions and clinical implications. Drugs 1993; 46(5): 795-804.
126. 126. Spinella MJ, Malik AB, Everitt J, Andersen TT. Design and synthesis of a specific endothelin 1 antagonist: effects on pulmonary vasoconstriction. Proc Natl Acad Sci USA 1991; 88: 7443-6.
127. A receptor. Life Sci 1992; 50: 247-55.
128. 128. Zuccarello M, Lewis AI, Rapoport RM. Endothelin ETA and ETB receptors in subarachnoid haemorrhage-induced cerebral vasospasm. Eur J Pharmacol 1994; 259: R1-R2.
129. 129. Mihara S, Fujimoto M. The endothelin ETA receptor-specific effect of 50-235, a nonpeptide endothelin antagonist. Eur J Pharmacol 1993; 246: 33-8.
130. 130. Ohlstein EH, Nambi P, Douglas SA, Edwards RM, Gellai M, Lago A, Leber JD, Cousins RD, Gao A, Frazee JS, Peishoff CE, Bean JW, Eggleston DS, Elshourbagy NA, Kumar C, Lee JA, Yue TL, Louden C, Brooks DP, Weinstock J, Feuerstein G, Poste G, Ruffolo RR, Gleason JG. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci USA 1994; 91: 8052-6.
131. 131. Stein PD, Hunt JT, Floyd DM, Moreland S, Dickinson KEJ, Mitchell C, Liu ECK, Webb ML, Murugesan N, Dickey J, McMullen D, Zhang R, Lee VG, Serafino R, Denaley C, Schaeffer TR, Kozlowski MJ. The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)N-(3,4-dimethyl-5-isoxazolyl)-1-naphtalen sulfonamide. J Med Chem 1994; 37: 329-31.
132. 132. Clozel M, Breu V, Gray GA, Kalina B, Löffler BM, Burri K, Cassal JM, Hirth G, Müller M, Neidhart W, Ramuz H. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 279: 228-35.
133. 133. Kiowski W, Sütsch G, Hunziker P. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346: 732-6.
134. 134. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, Fukuroda T, Fikami T, Ozaki S, Nagese T, Nishikibe M, Yano M. Biochemical and pharmacological profile of a potent and selective endothelin B receptor antagonist, BQ-788. Proc Natl Acad Sci USA 1994; 91: 4892-6.
135. 135. Riechers H, Albrecht HP, Amberg W, Baumann E, Bernard H, Bohm HJ, Klinge D, Kling A, Muller S, Raschack M, Unger L, Walker N, Wernet W. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. J Med Chem 1996; 3(11): 2123-8.